In a patient started on desvenlafaxine (Pristiq) for anxiety and depression whose PHQ‑8 and GAD‑7 scores remain elevated, what augmentation options can be added?

Augmentation Options for Desvenlafaxine Non-Response

Add bupropion SR or switch to cognitive behavioral therapy (CBT), as both augmentation strategies show similar efficacy with moderate certainty of evidence for patients who don't respond to initial SNRI treatment. 1

Evidence-Based Augmentation Strategies

The 2023 American College of Physicians guideline analyzing second-step treatments for major depressive disorder provides the strongest framework for your decision 1. This systematic review of 2,733 participants found that for patients who don't remit after initial antidepressant treatment:

Primary Augmentation Options (Similar Efficacy):

• Bupropion SR augmentation – Most studied option with moderate certainty evidence
• Buspirone augmentation – Similar efficacy to bupropion but higher discontinuation rates (20.6% vs 12.5%, P<0.001) 1
• Cognitive therapy augmentation – Comparable efficacy to medication augmentation with lower adverse event discontinuation (9.2% vs 18.8%) 1

The key finding: All three augmentation strategies (bupropion, buspirone, or CBT added to your current antidepressant) produced similar symptom relief, so choose based on tolerability and patient preference.

Atypical Antipsychotic Augmentation:

If first-line augmentation fails, consider:

• Aripiprazole – One trial showed higher remission rates (55.4% vs 34% with bupropion, P=0.031) 1
• Quetiapine – Evidence supports use in treatment-resistant depression 2, 3

However, atypical antipsychotics carry significant metabolic risks (weight gain averaging 11 pounds in one study 4) and should be reserved for patients who fail initial augmentation attempts 2.

Alternative: Switch Strategy

Switching desvenlafaxine to another antidepressant (escitalopram, duloxetine, sertraline, or vortioxetine) shows equivalent efficacy to augmentation 1. Four trials found no differences between various switch strategies, and two trials found switching versus augmenting with mirtazapine produced identical outcomes 1.

Clinical Decision Algorithm:

1. First verify adequate trial: Ensure patient has been on therapeutic dose (50-100 mg) for at least 8-12 weeks 5

2. Choose augmentation over switching if:

   • Patient has partial response (some symptom improvement)
   • Tolerating desvenlafaxine well
   • Prefers to avoid discontinuation symptoms

3. Select specific augmentation:

   • Bupropion SR: Best if patient has prominent fatigue, low energy, or concerns about sexual side effects
   • CBT: Best if patient prefers non-pharmacologic approach and has access to therapy (lower discontinuation rates)
   • Buspirone: Acceptable but expect higher discontinuation rates

4. Reserve atypical antipsychotics (aripiprazole, quetiapine) for patients who fail initial augmentation AND can tolerate metabolic monitoring

Important Caveats:

• The guideline found no evidence that comorbid anxiety affects comparative efficacy of augmentation strategies 1, so your patient's elevated GAD-7 shouldn't change the approach
• Depression severity also didn't predict differential response 1
• Avoid combining desvenlafaxine with MAOIs (14-day washout required) 5
• When adding bupropion, monitor for serotonin syndrome risk, though this is lower than with MAOI combinations

The evidence strongly supports that augmentation and switching strategies work equally well, so your choice depends primarily on patient preference, side effect profile tolerance, and access to psychotherapy 1.